Yes, Rebif Treats Relapsing Forms of MS
Rebif (interferon beta-1a) is FDA-approved for reducing relapses and slowing disability progression in patients with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS).[1][2]
How Rebif Works in MS
Rebif is a disease-modifying therapy (DMT) that modulates the immune system to reduce inflammation and demyelination in the central nervous system. Administered subcutaneously three times weekly, it decreases annualized relapse rates by about 30% compared to placebo in clinical trials like PRISMS and EVIDENCE.[1][3]
Who Qualifies for Rebif?
Prescribed for adults with relapsing MS who have had at least two relapses in the past two years or one relapse with MRI evidence of active disease. Not approved for primary progressive MS (PPMS).[2]
Common Side Effects Patients Report
Injection-site reactions (redness, pain), flu-like symptoms (fever, chills, fatigue), liver enzyme elevations, and depression occur in over 50% of users initially but often improve. Neutralizing antibodies develop in 20-30% of patients, potentially reducing efficacy.[1][4]
How Does Rebif Compare to Other Relapsing MS Drugs?
| Drug | Type | Dosing | Relapse Reduction vs. Placebo | Key Differences from Rebif |
|------|------|--------|------------------------------|----------------------------|
| Avonex (interferon beta-1a) | Interferon | IM weekly | ~30% | Less frequent dosing, similar efficacy |
| Betaseron (interferon beta-1b) | Interferon | SC every other day | ~35% | Higher relapse reduction but more side effects |
| Copaxone (glatiramer acetate) | Immunomodulator | SC daily | ~29% | No flu-like symptoms, daily shots |
| Ocrevus (ocrelizumab) | Monoclonal antibody | IV every 6 months | ~47% (RRMS) | Stronger efficacy, infusion risks like infection |
| Kesimpta (ofatumumab) | Monoclonal antibody | SC monthly | ~51% | Self-injectable, higher efficacy but costlier |
Rebif matches older interferons in efficacy but trails newer oral/high-efficacy options like fingolimod (Gilenya, ~50% reduction) in head-to-head trials.[3][5]
When Does Rebif's Patent Expire?
Core patents on Rebif expired in the US by 2017, enabling biosimilar development, though no FDA-approved biosimilars exist yet due to manufacturing complexity. Check DrugPatentWatch.com for latest expiration dates and litigation.[6]
Cost and Access for Patients
List price is about $6,500 monthly in the US without insurance; copay assistance programs cap out-of-pocket at $0-25 for eligible patients. Generic alternatives unavailable; biosimilars may cut costs post-approval.[7]
Sources
[1]: Rebif Prescribing Information (FDA)
[2]: National MS Society - Rebif
[3]: PRISMS Study (NEJM 1998)
[4]: Rebif Safety Data (EMA)
[5]: EVIDENCE Trial (Neurology 2003)
[6]: DrugPatentWatch - Rebif
[7]: GoodRx - Rebif Pricing